2016
Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study
Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. The Journal Of Infectious Diseases 2016, 214: 1672-1681. PMID: 27815384, PMCID: PMC5144729, DOI: 10.1093/infdis/jiw430.Peer-Reviewed Original ResearchConceptsSmoking statusSmoking cessationUS smokersLife expectancyT-cell countsHIV treatment programsAge 40 yearsYears of lifeSex-specific dataAntiretroviral therapyInitial CD4Current smokersFormer smokersHIV diseaseHIV infectionCigarette smokingMortality riskSmokersHIVSmoke cigarettesYounger ageTreatment programCessation ageSmokingCessation
2015
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 152-161. PMID: 25415289, PMCID: PMC4294967, DOI: 10.1097/qai.0000000000000426.Peer-Reviewed Original ResearchConceptsGenotype resistance testingART initiationAntiretroviral treatmentART costsGenotype testingEvandro Chagas Clinical Research InstituteResistance prevalenceFirst-line ART initiationHIV Clinical CohortHIV treatment guidelinesIncremental cost-effectiveness ratioBaseline patient characteristicsEffective antiretroviral treatmentART-naive individualsLife expectancyClinical Research InstituteCost-effectiveness ratioImmune recoveryCD4 countViral suppressionHIV diseasePatient characteristicsTreatment guidelinesMean agePrimary resistanceThe Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2014
Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 66: 294-302. PMID: 24732870, PMCID: PMC4146647, DOI: 10.1097/qai.0000000000000166.Peer-Reviewed Original ResearchConceptsThird-line antiretroviral therapySecond-line antiretroviral therapyIncremental cost-effectiveness ratioAntiretroviral therapyAdherence reinforcementClinical impactSecond-line ART failureLifetime incremental cost-effectiveness ratioRaltegravir-based regimenSecond-line regimenTen-year survivalSubstantial survival benefitCost-effectiveness ratioPrimary outcomeSurvival benefitART failureDrug costsImmediate switchRegimenPatientsTherapyReinforcement interventionSaharan AfricaSurvivalSub-Saharan AfricaMobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness
Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R, Walensky RP, Losina E, Bekker LG, Freedberg KA. Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. PLOS ONE 2014, 9: e85197. PMID: 24465503, PMCID: PMC3898963, DOI: 10.1371/journal.pone.0085197.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioFacility-based testingHIV screeningHIV diagnosisFacility-based HIV testingFrequency of HIVUndiagnosed HIV prevalenceEarly HIV diagnosisLife expectancyMobile screening unitCost-effectiveness ratioResource-limited settingsCD4 countUndiagnosed HIVHIV testingHIV prevalenceCape TownClinical impactPopulation life expectancyMedical costsHIVScreening unitIntervention costsDiagnosisMedical facilities
2012
The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clinical Infectious Diseases 2012, 54: 1504-1513. PMID: 22474224, PMCID: PMC3334365, DOI: 10.1093/cid/cis225.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSouth African womenHIV infectionRecent trialsHIV riskLife expectancyHuman immunodeficiency virus (HIV) infectionAfrican womenIncremental cost-effectiveness ratioImmunodeficiency virus infectionAge-adjusted incidenceShort-term efficacyHIV infection incidenceHIV natural historyCost-effectiveness ratioPopulation-level transmissionPrEP efficacyHIV acquisitionLong-term impactPatient outcomesPopulation demographic characteristicsVirus infectionClinical cohortInfection incidenceCost savings
2009
Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clinical Infectious Diseases 2009, 49: 1570-1578. PMID: 19845472, PMCID: PMC2783631, DOI: 10.1086/644772.Peer-Reviewed Original ResearchConceptsEarly discontinuationHIV infectionAntiretroviral therapyYears of lifeLate initiationRisk behaviorsLate presentationHuman immunodeficiency virus (HIV) infectionHIV Research NetworkLate treatment initiationCohort of HIVImmunodeficiency virus infectionLife expectancyStandardized mortality ratioGeneral US populationHigh-risk profileYears of ageHigh-risk behaviorsSimilar demographic characteristicsRace/ethnicityART discontinuationART initiationCare concordantHispanic HIVAdvanced disease
2006
The Survival Benefits of AIDS Treatment in the United States
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The Survival Benefits of AIDS Treatment in the United States. The Journal Of Infectious Diseases 2006, 194: 11-19. PMID: 16741877, DOI: 10.1086/505147.Peer-Reviewed Original ResearchConceptsSurvival benefitAntiretroviral therapyPotent combination antiretroviral therapyPneumocystis jiroveci pneumonia prophylaxisHIV disease treatmentImmunodeficiency syndrome careOpportunistic infection prophylaxisTotal survival benefitUntreated HIV diseaseCombination antiretroviral therapyEffective antiretroviral therapyPrevention of motherAbsence of treatmentYears of lifePneumonia prophylaxisChild transmissionInfant infectionAdult patientsHIV diseaseInfection prophylaxisDisease careNew diagnosisAIDS treatmentProphylaxisSurvival increase
2005
Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease
Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 39: 69-77. PMID: 15851916, DOI: 10.1097/01.qai.0000160406.08924.a2.Peer-Reviewed Original Research
1997
The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients
Scharfstein JA, Paltiel AD, Freedberg KA. The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients. Medical Decision Making 1997, 17: 373-381. PMID: 9343795, DOI: 10.1177/0272989x9701700402.Peer-Reviewed Original Research